Savara Inc SVRA
Savara Inc. (together with its subsidiaries "Savara," the "Company," "we," "our" or "us") is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim inhalation solution ("MOLBREEVI" or "molgramostim"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis ("autoimmune PAP"). MOLBREEVI is delivered via a proprietary eFlow® Nebulizer System (PARI Pharma GmbH, "PARI").
Our goal is to become a leader in rare respiratory therapeutics through the development and commercialization of novel, best-in-class medicines that address unmet medical needs in this field. Key elements of our strategy include:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $257.0K | $0 | — | $0 | $400.0K |
| SG&A | $42.1M | $25.0M | $15.7M | $10.9M | $12.3M | $14.3M | $13.1M | $10.7M | $11.1M | $2.8M |
| Total operating expenses | $123.5M | $103.2M | $60.0M | $38.8M | $41.5M | $49.6M | $79.0M | $70.0M | $30.0M | $11.3M |
| Operating income | -$123.5M | -$103.2M | -$60.0M | -$38.8M | -$41.5M | -$49.3M | -$79.0M | -$70.0M | -$30.0M | -$10.9M |
| Interest expense | — | — | — | — | — | — | — | — | $1.2M | $452.0K |
| Pre-tax income | -$118.8M | -$95.9M | -$54.7M | -$38.1M | -$43.0M | -$49.6M | -$78.2M | -$68.6M | -$33.4M | -$11.3M |
| Income tax | $0 | $9.0K | — | — | — | — | — | $7.1M | $3.6M | $357.0K |
| Net income | -$118.8M | -$95.9M | -$54.7M | -$38.1M | -$43.0M | -$49.6M | -$78.2M | -$61.5M | -$29.8M | -$10.9M |
| EPS, basic | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | — | — | — | — | — |
| EPS, diluted | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -1.95 | -1.85 | -1.76 | -5.62 |
| Shares, diluted (wtd. avg.) | $222.4M | $198.2M | $165.2M | $152.8M | $133.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $33.2M | $15.1M | $26.6M | $52.1M | $34.0M | $22.9M | $49.8M | $24.3M | $22.1M | $13.4M |
| Short-term investments | $202.5M | $181.2M | $135.7M | $73.8M | $127.2M | $59.3M | $72.0M | $86.5M | $72.2M | $0 |
| Total current assets | $241.6M | $202.1M | $165.9M | $129.0M | $165.0M | $85.1M | $124.1M | $113.3M | $97.9M | $14.6M |
| Property, plant and equipment | $100.0K | $165.0K | $270.0K | $51.0K | $73.0K | $156.0K | $352.0K | $522.0K | $925.0K | $793.0K |
| Goodwill | — | — | — | — | — | $0 | — | $26.9M | $27.1M | $3.1M |
| Total assets | $253.4M | $212.9M | $177.6M | $139.8M | $176.6M | $97.7M | $136.2M | $152.3M | $159.6M | $28.9M |
| Accounts payable | $5.8M | $4.5M | $3.5M | $1.3M | $1.4M | $2.6M | $3.4M | $3.9M | $2.8M | $536.0K |
| Short-term debt | $0 | — | — | — | $8.3M | — | — | — | — | — |
| Total current liabilities | $20.4M | $14.7M | $10.6M | $5.9M | $14.7M | $8.2M | $10.9M | $7.3M | $6.0M | $3.5M |
| Long-term debt | $29.9M | $26.6M | $26.3M | $26.1M | $17.3M | $25.1M | — | — | — | — |
| Total liabilities | $50.3M | $41.4M | $37.2M | $32.0M | $32.1M | $33.4M | $34.5M | $44.1M | $40.3M | $20.9M |
| Retained earnings | -$608.1M | -$489.2M | -$393.4M | -$338.7M | -$300.5M | -$257.5M | -$207.9M | -$129.7M | -$68.2M | -$38.4M |
| Total equity | $203.1M | $171.4M | $140.4M | $107.8M | $144.5M | $64.4M | $101.7M | $108.2M | $119.3M | -$35.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$101.0M | -$89.1M | -$51.1M | -$34.6M | -$40.1M | -$39.8M | -$45.1M | -$39.3M | -$28.2M | -$8.4M |
| Depreciation and amortisation | — | — | — | — | $100.0K | $300.0K | $300.0K | $526.0K | $363.0K | $346.0K |
| Stock-based compensation | $14.4M | $9.9M | $4.2M | $2.0M | $3.3M | $5.1M | $4.4M | $3.7M | $552.0K | $209.0K |
| Capital expenditure | $22.0K | $25.0K | $296.0K | $9.0K | $57.0K | $47.0K | $148.0K | $141.0K | $495.0K | $8.0K |
| Investing cash flow | -$18.4M | -$39.9M | -$57.1M | $52.6M | -$69.5M | $9.1M | $15.7M | -$13.6M | -$69.1M | -$8.0K |
| Financing cash flow | $137.8M | $117.6M | $82.8M | $87.0K | $120.8M | $3.7M | $54.9M | $55.2M | $106.1M | $5.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177353.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |